Contactless pulsed and continuous microdroplet release using photothermal liquid crystals

Abstract Targeted, on-demand delivery has been of interest using materials responsive to environmental stimuli. A delivery technique based on precise release of aqueous microdroplets from a liquid crystal (LC) medium with contactless stimulation is presented. A nematic LC is doped with a photothermal dye that produces heat under near IR light exposure. The heat is used to overcome the elastic strains in the LC phase, promoting the release of initially entrapped water droplets to the neighboring aqueous solution. Designing the geometry of LC-based emulsions and tuning the light intensity and position allows for manipulation of the release in two distinct modes defined as pulsated and continuous. In the pulsated mode, water droplets are released transiently from the casted water-in-LC emulsion layer based on sweeping by the moving isotropic-nematic phase boundary controlled by light. In the continuous mode, water droplets are ejected continuously from a droplet-shaped water-in-LC emulsion, due to a heating-induced internal flow controlled by light. The droplet release by contactless stimulation is used for the on-demand dosing of dopamine and its oxidizing reagent from isolated reservoirs to obtain an in situ reaction signal for a hydrogen peroxide assay. A new dual-mode release system developed with photothermal LCs holds potential in drug release, controlled mixing, and photothermal therapy

Investigation of pazopanib and human serum albumin interaction using spectroscopic and molecular docking approaches

Abstract Pazopanib (PAZ), a tyrosine kinase inhibitor, is used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). The FDA approved PAZ for RCC in 2009 and for STS in 2012. The antitumor activity of pazopanib, according to the degree of inhibition, shows different results depending on the dose. Renal cell carcinoma is the most sensitive carcinoma to pazopanib, with 77% inhibition at the 10 mg/kg dose. Clinical studies have shown 53% to 65% inhibition in carcinomas such as breast carcinoma, prostate carcinoma, and melanoma. Plasma proteins such as human serum albumin (HSA) have a critical role in transporting and storing bioactive components. This feature of HSA is very important for the development of cancer therapy. Here, we investigated the interaction between PAZ and HSA to evaluate their binding strength, binding types, and conformational change in HSA. We used spectroscopic methods to assess the drug–protein interaction. Fluorescence measurements revealed that the interaction of PAZ with HSA occurred via the static quenching mechanism. The calculated binding number and binding constants were 1.041 and 1.436 × 10⁶ M⁻¹, respectively, at 298.15 K based on fluorescence screening. The high binding constant and calculated Gibbs free energy at different temperatures showed spontaneous and strong binding. Circular dichroism measurements showed that the α-helix structure of HSA was retained as the secondary structure, with a slight reduction in its percentage after adding PAZ. Furthermore, molecular modeling studies suggested that the docking score of PAZ is higher than those of bicalutamide and ibuprofen, the drugs that were chosen as model competitors against PAZ. Accordingly, PAZ was found to replace bicalutamide and ibuprofen on the HSA binding site, which was also confirmed by UV absorption spectroscopy